HC Wainwright Has Positive Outlook for BRNS FY2025 Earnings

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) – Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Barinthus Biotherapeutics in a research note issued on Monday, November 17th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($1.77) for the year, up from their previous forecast of ($1.86). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.42) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Barinthus Biotherapeutics in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Stock Down 7.3%

Shares of Barinthus Biotherapeutics stock opened at $0.71 on Wednesday. Barinthus Biotherapeutics has a 12-month low of $0.64 and a 12-month high of $2.92. The stock has a market capitalization of $29.12 million, a P/E ratio of -0.38 and a beta of -0.70. The stock has a 50 day moving average price of $1.21 and a two-hundred day moving average price of $1.15.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics at the end of the most recent reporting period. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.